Back to Search
JONATHAN SALTER, MD
MD
Internal Medicine Physician
NPI: 1700318706IndividualAccepts Medicare
Specialties, Licenses & Credentials
Student in an Organized Health Care Education/Training Program
Student in an Organized Health Care Education/Training Program
Code: 390200000X
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
ME146066(FL)
Education
OTHER
Class of 2017
Research & Publications (20)
Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer.
PMID 19247830·Breast Cancer Res Treat·2010
8-other
Variability in bleeding phenotype in Amish carriers of haemophilia B with the 31008 C-->T mutation.
PMID 18721150·Haemophilia·2009
4-observational
The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer.
PMID 18592370·Breast Cancer Res Treat·2009
8-other
The digital workshop: exploring the use of interactive and immersive visualisation tools in participatory planning.
PMID 18558460·J Environ Manage·2009
8-other
APOBEC3G subunits self-associate via the C-terminal deaminase domain.
PMID 18842592·J Biol Chem·2008
8-other
Structural effects of nucleobase variations at key active site residue Ade38 in the hairpin ribozyme.
PMID 18596253·RNA·2008
8-other
ESR1 gene amplification in breast cancer: a common phenomenon?
PMID 18583966·Nat Genet·2008
4-observational
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
PMID 18227529·J Clin Oncol·2008
2-rct
A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer.
PMID 17679728·J Clin Oncol·2007
3-trial
Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.
PMID 17228000·J Natl Cancer Inst·2007
8-other
The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo.
PMID 17876043·Mol Cancer Ther·2007
7-preclinical
Response of mitochondrial reactive oxygen species generation to steady-state oxygen tension: implications for hypoxic cell signaling.
PMID 16963616·Am J Physiol Heart Circ Physiol·2007
7-preclinical
Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy.
PMID 17133270·Br J Cancer·2007
8-other
Clinical trial: effects of tegaserod on gastric motor and sensory function in patients with functional dyspepsia.
PMID 17892526·Aliment Pharmacol Ther·2007
2-rct
BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial.
PMID 16777318·Cancer Lett·2007
2-rct
Water in the active site of an all-RNA hairpin ribozyme and effects of Gua8 base variants on the geometry of phosphoryl transfer.
PMID 16411744·Biochemistry·2006
8-other
Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer.
PMID 16467120·Clin Cancer Res·2006
2-rct
Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status.
PMID 16497822·Ann Oncol·2006
2-rct
Nanostructures of APOBEC3G support a hierarchical assembly model of high molecular mass ribonucleoprotein particles from dimeric subunits.
PMID 17079235·J Biol Chem·2006
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1400 NW 12TH AVE
MIAMI, FL 33136 - Phone
- (305) 243-1960
Quick Facts
- NPI
- 1700318706
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 9
- Publications
- 20
Are you this provider?
Claim Your Profile